UNASSIGNED: 82 Background: Metastatic @entity320 is a nearly uniformly fatal disease. Systemic therapy has notable but limited success. Novel therapeutic strategies are urgently needed. To that end, we've pursued combinatorial therapeutics using conventional chemotherapy added to an inhibitor of angiogenesis (bevacizumab) with some evidence of clinical benefit. Preliminary analysis of one of our trials suggested a previously unrecognized immunomodulatory effect of bevacizumab when added to chemotherapy in @entity1 with @entity320 , and this may have a potential impact on clinical outcome. Herein we evaluate the immunomodulatory effect of bevacizumab when added to chemotherapy in @entity1 with @entity320 . METHODS: We measured levels of peripheral blood mononuclear cell phenotypes in addition to 42 cytokines, chemokines and growth factors in plasma of 55 @entity1 who received albumin-bound @entity1311 and @entity3003 (AC) and of 73 @entity1 who received AC with bevacizumab (ACB) on clinical trials N057e and N0775 respectively. The relative percent change in PBMC cell counts and cytokine levels were determined from baseline at their restaging evaluation after two cycles of therapy. The Mann Whitney U test was used to compare responses between the groups. RESULTS: There was a significant increase in @entity9350 (+)type 1 macrophages in the group that received ACB (35.3%, -11.8-142.7%) compared to AC (-11.6%, -45.9-38.3%; p=0.004). There was a significant decrease in @entity650 in the group that received ACB (-42.4%, -87.7-0.0%) compared to AC (28.4%, -37.4-480%; p=0.0018). CONCLUSIONS: The addition of bevacizumab to chemotherapy for the treatment of @entity320 modulates cellular immunity and a pro-inflammatory cytokine. @entity1 who received bevacizumab had a significant increase in @entity9350 (+) type 1 macrophages and a significant decrease in @entity650 . Clinical significance of these findings is the subject of ongoing work.

Immunomodulatory effects of bevacizumab in metastatic XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity650 :: ('3569', 'Gene') :: ['IL-6'] @entity3003 :: ('MESH:D016190', 'Chemical') :: ['carboplatin'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel'] @entity9350 :: ('1236', 'Gene') :: ['CD197'] @entity320 :: ('MESH:D008545', 'Disease') :: ['metastatic melanoma', 'malignant melanoma']
@entity320 :: (MESH:D008545,Disease) :: ['malignant melanoma']
